- Home
- BAK vs PVLA Comparison
BAK vs PVLA Comparison
Compare BAK & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAK | PVLA |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BAK | PVLA |
|---|---|---|
| Price | $3.62 | $78.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 17 |
| Target Price | $4.40 | ★ $145.24 |
| AVG Volume (30 Days) | ★ 1.5M | 235.4K |
| Earning Date | 02-26-2026 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,841,708,237.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.32 | $12.60 |
| 52 Week High | $4.83 | $114.69 |
Technical Indicators
Market Signals| Indicator | BAK | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 38.63 |
| Support Level | $3.35 | $72.23 |
| Resistance Level | $3.97 | $82.46 |
| Average True Range (ATR) | 0.20 | 5.90 |
| MACD | 0.01 | -1.99 |
| Stochastic Oscillator | 61.50 | 18.90 |
Price Performance
Historical ComparisonAbout BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.